Abstract
The results of administration of cholestyramine to 19 patients for periods of two to 21 months are reported.
All patients consistently taking the drug obtained a significant reduction in the serum cholesterol. The average reduction was 26 per cent and the range was from 16 to 52 per cent.
Cholestyramine acts as a bile acid sequestering resin, causing an increased loss of bile salts (cholates) in the stool. The drug acts by increasing the normal excretory pathway for cholesterol.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Gallo D. G., Sheffner A. L. The disposition of orally administered cholestyraminec14. Proc Soc Exp Biol Med. 1965 Oct;120(1):91–93. [PubMed] [Google Scholar]
- HASHIM S. A., VANITALLIE T. B. CHOLESTYRAMINE RESIN THERAPY FOR HYPERCHOLESTEREMIA: CLINICAL AND METABOLIC STUDIES. JAMA. 1965 Apr 26;192:289–293. doi: 10.1001/jama.1965.03080170017004. [DOI] [PubMed] [Google Scholar]
- TENNENT D. M., SIEGEL H., ZANETTI M. E., KURON G. W., OTT W. H., WOLF F. J. Plasma cholesterol lowering action of bile acid binding polymers in experimental animals. J Lipid Res. 1960 Oct;1:469–473. [PubMed] [Google Scholar]